Literature DB >> 34981426

Cortical Spreading Depolarizations in a Mouse Model of Subarachnoid Hemorrhage.

James H Lai1,2, Tao Qin1, Sava Sakadžić3, Cenk Ayata1,4, David Y Chung5,6.   

Abstract

BACKGROUND: Cortical spreading depolarizations (CSDs) are associated with worse outcomes in patients with aneurysmal subarachnoid hemorrhage (SAH). Animal models are required to assess whether CSDs can worsen outcomes or are an epiphenomenon; however, little is known about the presence of CSDs in existing animal models. Therefore, we designed a study to determine whether CSDs occur in a mouse model of SAH.
METHODS: A total of 36 mice were included in the study. We used the anterior prechiasmatic injection model of SAH under isoflurane anesthesia. A needle was inserted through the mouse olfactory bulb with the point terminating at the base of the skull, and arterial blood or saline (100 µl) was injected over 10 s. Changes in cerebral blood volume over the entire dorsal cortical surface were assessed with optical intrinsic signal imaging for 5 min following needle insertion.
RESULTS: CSDs occurred in 100% of mice in the hemisphere ipsilateral to olfactory bulb needle insertion (CSD1). Saline-injected mice had 100% survival (n = 10). Blood-injected mice had 88% survival (n = 23 of 26). A second, delayed, CSD ipsilateral to CSD1 occurred in 31% of blood-injected mice. An increase in the time interval between CSD1 and blood injection was associated with the occurrence of a second CSD in blood-injected mice (mean intervals 26.4 vs. 72.7 s, p < 0.0001, n = 18 and 8). We observed one blood-injected animal with a second CSD in the contralateral hemisphere and observed terminal CSDs in mice that died following SAH injection.
CONCLUSIONS: The prechiasmatic injection model of SAH includes CSDs that occur at the time of needle insertion. The occurrence of subsequent CSDs depends on the timing between CSD1 and blood injection. The mouse prechiasmatic injection model could be considered an SAH plus CSD model of the disease. Further work is needed to determine the effect of multiple CSDs on outcomes following SAH.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society.

Entities:  

Keywords:  Brain aneurysm; Cortical spreading depression; Delayed cerebral ischemia; Mouse model; Neurocritical care

Mesh:

Year:  2022        PMID: 34981426      PMCID: PMC9250554          DOI: 10.1007/s12028-021-01397-9

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.532


  32 in total

1.  Spreading depression in the olfactory bulb of rats: reliable initiation and boundaries of propagation.

Authors:  T Amemori; N A Gorelova; J Bures
Journal:  Neuroscience       Date:  1987-07       Impact factor: 3.590

Review 2.  Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations.

Authors:  Daniela Pietrobon; Michael A Moskowitz
Journal:  Nat Rev Neurosci       Date:  2014-06       Impact factor: 34.870

3.  Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association.

Authors:  E Sander Connolly; Alejandro A Rabinstein; J Ricardo Carhuapoma; Colin P Derdeyn; Jacques Dion; Randall T Higashida; Brian L Hoh; Catherine J Kirkness; Andrew M Naidech; Christopher S Ogilvy; Aman B Patel; B Gregory Thompson; Paul Vespa
Journal:  Stroke       Date:  2012-05-03       Impact factor: 7.914

4.  Microemboli may link spreading depression, migraine aura, and patent foramen ovale.

Authors:  Ala Nozari; Ergin Dilekoz; Inna Sukhotinsky; Thor Stein; Katharina Eikermann-Haerter; Christina Liu; Yumei Wang; Matthew P Frosch; Christian Waeber; Cenk Ayata; Michael A Moskowitz
Journal:  Ann Neurol       Date:  2010-02       Impact factor: 10.422

Review 5.  Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference.

Authors:  Michael N Diringer; Thomas P Bleck; J Claude Hemphill; David Menon; Lori Shutter; Paul Vespa; Nicolas Bruder; E Sander Connolly; Giuseppe Citerio; Daryl Gress; Daniel Hänggi; Brian L Hoh; Giuseppe Lanzino; Peter Le Roux; Alejandro Rabinstein; Erich Schmutzhard; Nino Stocchetti; Jose I Suarez; Miriam Treggiari; Ming-Yuan Tseng; Mervyn D I Vergouwen; Stefan Wolf; Gregory Zipfel
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

Review 6.  Delayed neurological deterioration after subarachnoid haemorrhage.

Authors:  R Loch Macdonald
Journal:  Nat Rev Neurol       Date:  2013-12-10       Impact factor: 42.937

7.  Mechanisms of microthrombi formation after experimental subarachnoid hemorrhage.

Authors:  M Sabri; J Ai; K Lakovic; J D'abbondanza; D Ilodigwe; R L Macdonald
Journal:  Neuroscience       Date:  2012-08-16       Impact factor: 3.590

8.  A call for transparent reporting to optimize the predictive value of preclinical research.

Authors:  Story C Landis; Susan G Amara; Khusru Asadullah; Chris P Austin; Robi Blumenstein; Eileen W Bradley; Ronald G Crystal; Robert B Darnell; Robert J Ferrante; Howard Fillit; Robert Finkelstein; Marc Fisher; Howard E Gendelman; Robert M Golub; John L Goudreau; Robert A Gross; Amelie K Gubitz; Sharon E Hesterlee; David W Howells; John Huguenard; Katrina Kelner; Walter Koroshetz; Dimitri Krainc; Stanley E Lazic; Michael S Levine; Malcolm R Macleod; John M McCall; Richard T Moxley; Kalyani Narasimhan; Linda J Noble; Steve Perrin; John D Porter; Oswald Steward; Ellis Unger; Ursula Utz; Shai D Silberberg
Journal:  Nature       Date:  2012-10-11       Impact factor: 49.962

Review 9.  Spreading depression as a preclinical model of migraine.

Authors:  Andrea M Harriott; Tsubasa Takizawa; David Y Chung; Shih-Pin Chen
Journal:  J Headache Pain       Date:  2019-05-02       Impact factor: 7.277

10.  Delayed Cerebral Ischemia After Subarachnoid Hemorrhage: Experimental-Clinical Disconnect and the Unmet Need.

Authors:  Fumiaki Oka; David Y Chung; Michiyasu Suzuki; Cenk Ayata
Journal:  Neurocrit Care       Date:  2020-02       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.